Fully understand this study and voluntarily sign the ICF.
Age 18-75 years, no gender restriction.
Patients with locally advanced or recurrent/metastatic squamous and/or non-squamous non-small cell lung cancer confirmed by histology/cytology, unsuitable for radical therapy.
You may not be if
Medical history, CT scan, or MRI indicates the presence of CNS metastases.
Other malignancies within 5 years.
Any other reason deeming the participant unsuitable for the study, as judged by the investigator.
Clareo Health | Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
